Cargando…
Deregulation of HLA-I in cancer and its central importance for immunotherapy
It is now well accepted that many tumors undergo a process of clonal selection which means that tumor antigens arising at various stages of tumor progression are likely to be represented in just a subset of tumor cells. This process is thought to be driven by constant immunosurveillance which applie...
Autores principales: | Hazini, Ahmet, Fisher, Kerry, Seymour, Len |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344275/ https://www.ncbi.nlm.nih.gov/pubmed/34353849 http://dx.doi.org/10.1136/jitc-2021-002899 |
Ejemplares similares
-
Tackling HLA Deficiencies Head on with Oncolytic Viruses
por: Fisher, Kerry, et al.
Publicado: (2021) -
Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021) -
Review of MicroRNA Deregulation in Oral Cancer. Part I
por: Kolokythas, Antonia, et al.
Publicado: (2011) -
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
por: de Vries, Natasja L., et al.
Publicado: (2023) -
The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
por: Attia, Jiji V. D., et al.
Publicado: (2020)